PROCEPT BioRobotics Corporation (PRCT) Stock Analysis & Winston Score

PROCEPT BioRobotics makes a surgical robot called AquaBlation therapy, which treats an enlarged prostate — a common condition in older men. The robot uses a precise waterjet to remove excess prostate tissue, guided by ultrasound imaging. The company sells its AquaBeam Robotic System to hospitals and urology centers, primarily in the United States. The company makes money by selling the AquaBeam robot itself and then earning recurring revenue from the single-use disposable handpieces required for each procedure. This razor-and-blade model means revenue grows as more procedures are performed on installed machines. PROCEPT operates mainly in the US but is expanding internationally. With a gross margin around 63%, the underlying unit economics are solid, but the company is still spending heavily on sales and growth, resulting in significant operating losses. The key growth driver is continued adoption of AquaBlation as an alternative to traditional prostate surgery, though the main risk is the high cost of the system limiting hospital uptake.